JP2023537760A - タンパク質の製造工程 - Google Patents

タンパク質の製造工程 Download PDF

Info

Publication number
JP2023537760A
JP2023537760A JP2023510446A JP2023510446A JP2023537760A JP 2023537760 A JP2023537760 A JP 2023537760A JP 2023510446 A JP2023510446 A JP 2023510446A JP 2023510446 A JP2023510446 A JP 2023510446A JP 2023537760 A JP2023537760 A JP 2023537760A
Authority
JP
Japan
Prior art keywords
aspects
relative abundance
glycans
residue
linked glycans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023510446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537760A5 (https=
Inventor
モーガン ルイス，アマンダ
ロバート マスカス，ダニエル
リチャード ガー，エリック
ケイ ウォレル，ダイアン
トーマス ルドウィッグ，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023537760A publication Critical patent/JP2023537760A/ja
Publication of JP2023537760A5 publication Critical patent/JP2023537760A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023510446A 2020-08-14 2021-08-13 タンパク質の製造工程 Pending JP2023537760A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066122P 2020-08-14 2020-08-14
US63/066,122 2020-08-14
PCT/US2021/046029 WO2022036275A2 (en) 2020-08-14 2021-08-13 Manufacturing process for protein

Publications (2)

Publication Number Publication Date
JP2023537760A true JP2023537760A (ja) 2023-09-05
JP2023537760A5 JP2023537760A5 (https=) 2024-08-22

Family

ID=77693592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023510446A Pending JP2023537760A (ja) 2020-08-14 2021-08-13 タンパク質の製造工程

Country Status (6)

Country Link
US (1) US20230313259A1 (https=)
EP (1) EP4196597A2 (https=)
JP (1) JP2023537760A (https=)
KR (1) KR20230042125A (https=)
CN (1) CN116391043A (https=)
WO (1) WO2022036275A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538881A (ja) * 2020-08-14 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー タンパク質の製造方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118256580B (zh) * 2022-12-27 2025-06-24 信立泰(苏州)药业有限公司 一种用于表达度拉糖肽的cho细胞的低温培养方法
CN119511070B (zh) * 2024-11-05 2026-01-30 河北工业大学 一种用于电机GW绝缘材料的Wiener-IG融合寿命预测方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511224A (ja) * 2002-12-23 2006-04-06 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質製造のための哺乳類細胞培養方法を用いる生成物品質の増大
JP2007508003A (ja) * 2003-10-10 2007-04-05 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核生物細胞におけるポリペプチドの大規模生産方法及びそれに適した培養容器
JP2009520503A (ja) * 2005-12-20 2009-05-28 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
JP2011512852A (ja) * 2008-03-12 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー 培地中にｐＣＯ２の一定の含有率を有する組換えタンパク質を産生するための方法
JP2013524824A (ja) * 2010-04-26 2013-06-20 ノバルティス アーゲー 改良型細胞培養培地
JP2018521676A (ja) * 2015-08-04 2018-08-09 リヒター ゲデオン エヌワイアールティー． 組換えタンパク質のガラクトース含有量を増加させる方法
JP2018523481A (ja) * 2015-08-17 2018-08-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05006523A (es) * 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
CA2797356C (en) * 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
PT2837680T (pt) * 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
CA2969225C (en) * 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
CA3056011A1 (en) * 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511224A (ja) * 2002-12-23 2006-04-06 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質製造のための哺乳類細胞培養方法を用いる生成物品質の増大
JP2007508003A (ja) * 2003-10-10 2007-04-05 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核生物細胞におけるポリペプチドの大規模生産方法及びそれに適した培養容器
JP2009520503A (ja) * 2005-12-20 2009-05-28 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
JP2011512852A (ja) * 2008-03-12 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー 培地中にｐＣＯ２の一定の含有率を有する組換えタンパク質を産生するための方法
JP2013524824A (ja) * 2010-04-26 2013-06-20 ノバルティス アーゲー 改良型細胞培養培地
JP2018521676A (ja) * 2015-08-04 2018-08-09 リヒター ゲデオン エヌワイアールティー． 組換えタンパク質のガラクトース含有量を増加させる方法
JP2018523481A (ja) * 2015-08-17 2018-08-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538881A (ja) * 2020-08-14 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー タンパク質の製造方法

Also Published As

Publication number Publication date
WO2022036275A2 (en) 2022-02-17
KR20230042125A (ko) 2023-03-27
US20230313259A1 (en) 2023-10-05
CN116391043A (zh) 2023-07-04
WO2022036275A3 (en) 2022-05-12
EP4196597A2 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
JP4384400B2 (ja) 適当にグリコシル化されたポリペプチドの製造方法
CN106589132B (zh) 组合物和用于生产组合物的方法
AU2002255600B2 (en) Efficient recovery of correctly refolded proteins
EP2971040B1 (en) Methods of cell culture
JP2023537760A (ja) タンパク質の製造工程
JP4234647B2 (ja) 高い比活性を有するエリスロポエチン
EP2971014A1 (en) Methods of cell culture
EP2968549A1 (en) Methods of cell culture
EP3400241B1 (en) Modulation of afucosylated species in a monoclonal antibody composition
WO2014159494A1 (en) Methods of cell culture
EP4567428A2 (en) Treatment with highly silylated igg compositions
EP3969564A1 (en) Method for reducing methionine oxidation in recombinant proteins
AU2017206012A1 (en) Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
CN114990049B (zh) 一种同时调节细胞表达产物的糖型和电荷异质性的方法
CA3002120A1 (en) Methods for modulating production profiles of recombinant proteins
US20230323422A1 (en) Method of making protein
CN116583536A (zh) 制造蛋白质的方法
EP4248218A1 (en) Sialylated glycoproteins
CN121712803A (zh) 控制抗体糖基化谱的方法
EA050771B1 (ru) Лечение композициями высокосиалилированного igg

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240813

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413